These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 24438369)
1. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. Min MX; Weinberg DI; McCabe RP J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369 [TBL] [Abstract][Full Text] [Related]
2. [Optimized thiopurine treatment in chronic inflammatory bowel disease]. Kiszka-Kanowitz M; Theede K; Nielsen AM Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625 [TBL] [Abstract][Full Text] [Related]
3. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102 [TBL] [Abstract][Full Text] [Related]
4. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle? Roberts RL; Gearry RB; Barclay ML Pharmacogenomics; 2010 Nov; 11(11):1505-8. PubMed ID: 21121769 [No Abstract] [Full Text] [Related]
5. [Optimized thiopurine treatment in chronic inflammatory bowel disease]. Kiszka-Kanowitz M; Theede K; Nielsen AM Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005 [TBL] [Abstract][Full Text] [Related]
6. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182 [TBL] [Abstract][Full Text] [Related]
7. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682 [TBL] [Abstract][Full Text] [Related]
8. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease. Wall GC; Muktar H; Effken C; Mahajan PB Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117 [TBL] [Abstract][Full Text] [Related]
9. Thiopurine therapy in inflammatory bowel disease. Ha C; Dassopoulos T Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143 [TBL] [Abstract][Full Text] [Related]
10. Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond. Fong SC; Blaker PA; Arenas-Hernandez M; Marinaki AM; Sanderson JD Biomark Med; 2015; 9(1):51-65. PubMed ID: 25605455 [TBL] [Abstract][Full Text] [Related]
11. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication? Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756 [TBL] [Abstract][Full Text] [Related]
12. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Leong RW; Gearry RB; Sparrow MP Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713 [TBL] [Abstract][Full Text] [Related]
13. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529 [TBL] [Abstract][Full Text] [Related]
14. Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease. Sheikh M; Nelson-Piercy C; Duley J; Florin T; Ansari A J Crohns Colitis; 2015 Aug; 9(8):680-4. PubMed ID: 25939351 [TBL] [Abstract][Full Text] [Related]
15. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002 [TBL] [Abstract][Full Text] [Related]
16. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Seinen ML; de Boer NK; Smid K; van Asseldonk DP; Bouma G; van Bodegraven AA; Peters GJ Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1085-90. PubMed ID: 22132961 [TBL] [Abstract][Full Text] [Related]
17. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442 [TBL] [Abstract][Full Text] [Related]
18. Thiopurine therapy: when to start and when to stop. McGovern DP; Travis SP Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):219-23. PubMed ID: 12610314 [TBL] [Abstract][Full Text] [Related]
19. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793 [TBL] [Abstract][Full Text] [Related]
20. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. Govani SM; Higgins PD J Crohns Colitis; 2010 Oct; 4(4):444-9. PubMed ID: 21122542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]